At Mayo Clinic Laboratories, we believe all patients deserve access to world-class diagnostic care. We work with hospitals and healthcare providers around the world to deliver unparalleled expertise and innovative diagnostic evaluations that solve the most complicated cases.
Fully integrated with Mayo Clinic and backed by more than 150 years of clinical experience, Mayo Clinic Laboratories was built upon a tradition of knowledge sharing to improve healthcare around the world. When you work with us, you gain access to the world’s most sophisticated test menu, world-renowned experts, and educational opportunities to strengthen your practice, advance knowledge, and improve patient outcomes.
70+
70+ countries connected to Mayo Clinic Laboratories
4.5 million
4.5 Million patients served annually
90+
90+ new tests launched each year
25.6 million
25.6 Million tests performed annually
Focused on quality
At Mayo Clinic Laboratories, test development is based on patient need and guided by quality management protocols modeled on standards and guidelines from the Clinical and Laboratory Standards Institute. Our extensive test validation includes a breadth of specimens with rare abnormalities. Our laboratories are CLIA-certified and CAP-accredited, and we participate in U.S. and international proficiency programs.
Commitment to education
The exchange of knowledge is a founding principle of Mayo Clinic. In this tradition, we provide a wide range of educational offerings to help our clients increase understanding.
Enhanced patient outcomes
Mayo Clinic Laboratories is dedicated to the health and well-being of our patients, which means helping providers deliver care in their local settings through the utilization of our comprehensive subspecialty test menu. Our mission is grounded in our belief that the patient’s needs are paramount, and our clients receive access to:
“We treat all of the specimens we receive with the same high degree of care and quality, regardless of where the sample is coming from. We could be testing a sample from a patient that lives in Rochester, Minnesota, or from someone that lives halfway across the world.”
Bobbi Pritt, M.D., Director of the Clinical Parasitology Laboratory
OUR DIFFERENCE
The latest
Mary Jo Williamson, chief administrative officer of Mayo Clinic Laboratories, joins the “Fierce Healthcare” podcast to discuss how organizations can cultivate resiliency and agility amidst a changing healthcare landscape.
Mary Jo Williamson, chief administrative officer of Mayo Clinic Laboratories, joins the “Fierce Healthcare” podcast to discuss how organizations can cultivate resiliency and agility amidst a changing healthcare landscape.
Maryam Shahi, M.D., explains how Mayo Clinic Laboratories' unique biomarker test (TEST ID: AFOLR) determines which patients would likely benefit from a new treatment for recurrent epithelial ovarian cancer. Disease recurrence is common, and about one-third of patients respond to the new medication.
The most successful laboratory outreach programs recognize the importance of serving multiple customers. From provider to patient to healthcare consumer, the laboratory has an opportunity to serve them all with high-quality results and excellent service. When aligning testing with community awareness and patient needs, the laboratory outreach program can strategically plan for future success.
In this episode of “Lab Medicine Rounds,” host Justin Kreuter, M.D., speaks with Chancey Christenson, M.D., about the lab's important role in healthcare.
Mayo Clinic Laboratories has marked a significant advancement in the fight against Alzheimer's disease with the introduction of an innovative diagnostic test. This noninvasive blood test accurately detects the p-Tau217 biomarker, indicative of amyloid beta accumulation in the brain. This test is set to transform the approach to Alzheimer's disease management, offering a convenient and less invasive alternative to traditional diagnostic methods.
Maria Alice Willrich, Ph.D., explains how Mayo Clinic Laboratories' new assay provides therapeutic drug monitoring of risankizumab, or RISA. Test results help guide care for patients with plaque psoriasis, psoriatic arthritis, and Crohn's disease.
Register now – June 13, 2024: This webinar will provide a brief history of the FDA’s interest in LDTs and review the new requirements in detail, serving as an introduction to medical device regulations in the context of a clinical laboratory.
Mayo Clinic Laboratories introduces an advancement in the management of Crohn's disease with the release of a new laboratory test that measures Risankizumab levels in patients. This test will advance the therapeutic monitoring of Crohn's disease, enabling personalized treatment approaches.
As we prepare to celebrate this year's Lab Week, the Mayo Collaborative Services Education team not only wants to highlight your important work as medical laboratory professionals and pathologists, but also help you feel more confident in your role by sharing the following educational resources that may give you additional knowledge and opportunities to advance in your career.
Medical Laboratory Professionals Week, also known as Lab Week, provides us with the opportunity to increase our understanding of and appreciation for clinical laboratory personnel. We celebrate their efforts to provide critical answers for patients every day and drive innovation in the field of medicine.
Mayo Clinic Laboratories introduces the Inherited Parkinson’s Disease Gene Panel (Mayo ID: PARDP), a collaborative breakthrough poised to transform Parkinson’s disease diagnosis and treatment. Led by Rodolfo Savica, M.D., Ph.D., and Zhiyv (Neal) Niu, Ph.D., this comprehensive test offers unparalleled insights into Parkinson’s genetics, unveiling novel gene associations and enhancing diagnostic precision through next-generation sequencing. The panel’s capabilities include detecting subtle genetic variations and identifying familial patterns, promising personalized medicine advancements.
Alicia Algeciras-Schimnich, Ph.D., discusses Mayo Clinic Laboratories’ new noninvasive plasma biomarker assay for Alzheimer’s disease, an accessible, highly accurate testing option for individuals age 50 and above who are experiencing mild cognitive impairment or early dementia. Positive test results can confirm amyloid beta pathology and facilitate access to disease-modifying therapies.